false
Catalog
Workshop: Injectable Opioid Agonist Treatment (iOA ...
Injectable Opioid Agonist Treatment (iOAT) and Sho ...
Injectable Opioid Agonist Treatment (iOAT) and Short Acting Opioid Strategies for Fentanyl Use: Bridging International Strategies with Practical Implementation in the USA
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
In a recent discussion, a group of experts explored the potential of injectable opioid agonist treatment (IOT) for opioid use disorder, focusing on strategies used in Canada that may offer new approaches in the US. Dr. Jeremy Welloff, Dr. Julian Raffoul, and Dr. Emily Casey highlighted the use of intravenous (IV) hydromorphone and diacetylmorphine, contrasting these approaches with the US system, which lacks such options due to regulatory hurdles.<br /><br />IOT, or heroin-assisted treatment, has historical roots and substantial evidence from international studies supporting its efficacy, particularly for patients who struggle with traditional treatments like methadone or buprenorphine. The Canadian model demonstrates increased retention in treatment and reduced illicit drug use, although safety risks such as increased overdose rates are noted.<br /><br />Dr. Casey emphasized the practical application of these methods within hospital settings at the University of Pennsylvania, using patient-controlled analgesia and novel induction methods to stabilize patients suffering from withdrawal. The approach aims to keep patients in treatment longer, thereby improving outcomes.<br /><br />Dr. Raffoul shared experiences from Vanderbilt, where IV hydromorphone bridges were used to manage severe withdrawal symptoms effectively, sometimes leading to high-dose buprenorphine inductions. This method prioritizes patient stabilization and engagement in treatment to prevent withdrawal-driven relapse.<br /><br />The panel concluded that despite existing regulatory challenges in the US, the Canadian model provides valuable insights. The history of opioid treatment in the US, influenced by the Harrison Narcotics Act, continues to impact current practices, highlighting the need for evolving strategies to manage opioid use disorder effectively.
Keywords
injectable opioid agonist treatment
opioid use disorder
Canada
US
IV hydromorphone
diacetylmorphine
regulatory hurdles
heroin-assisted treatment
treatment retention
University of Pennsylvania
Vanderbilt
withdrawal symptoms
Harrison Narcotics Act
The content on this site is intended solely to inform and educate medical professionals. This site shall not be used for medical advice and is not a substitute for the advice or treatment of a qualified medical professional.
400 Massasoit Avenue
Suite 108
East Providence, RI 02914
cmecpd@aaap.org
Privacy
About
Advocacy
Membership
Fellowship
Education and Resources
Training Events
×
Please select your language
1
English